FIELD: organic chemistry; pharmaceutical industry.
SUBSTANCE: invention relates to use of a pharmaceutical composition containing a compound of formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient for preventing or treating pulmonary fibrosis, where the compound of formula 1 has the structure
in which R is a linear or branched alkyl group containing 1–10 carbon atoms.
EFFECT: invention provides preventing or treating oxidative stress-induced pulmonary fibrosis without any significant side effects.
8 cl, 10 dwg, 1 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATING ACUTE RENAL INJURY CAUSED BY CONTRAST AGENT | 2021 |
|
RU2817980C1 |
| NOVEL PYRAZOLE DERIVATIVES | 2022 |
|
RU2816835C1 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| PYRAZOLINE DIONE DERIVATIVES AS NADPH-OXIDASE INHIBITORS | 2010 |
|
RU2569855C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS | 2021 |
|
RU2803733C1 |
| HETEROCYCLIC COMPOUNDS USED IN TREATMENT OF AGE AND DIABETIC VASCULAR COMPLICATION | 2002 |
|
RU2291154C2 |
| 2-PYRAZINONE DERIVATIVES FOR TREATING DISEASES OR CONDITIONS WHERE INHIBITING NEUTROPHIL ELASTASE ACTIVITY IS USEFUL | 2007 |
|
RU2448098C2 |
| PYRIDOPYRIMIDINONE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2818954C1 |
| PYRAZOLOPYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | 2009 |
|
RU2569303C2 |
| MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2820540C2 |
